Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

BioPharma Terug naar discussie overzicht

CENTESSA (CNTA)

2 Posts
| Omlaag ↓
  1. [verwijderd] 8 juni 2022 15:56
    Centessa Pharmaceuticals (NASDAQ:CNTA) Lifted to “Buy” at Zacks Investment Research
    Posted by admin on Jun 6th, 202

    Pharmaceuticals logoCentessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $3.50 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 10.06% from the stock’s current price.

    According to Zacks, “Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom. “

    Get Centessa Pharmaceuticals alerts:
    Enter Your Email Address
    A number of other equities research analysts also recently commented on CNTA. The Goldman Sachs Group cut their price objective on Centessa Pharmaceuticals from $12.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 24th. Morgan Stanley decreased their price objective on shares of Centessa Pharmaceuticals from $19.00 to $15.00 and set an “overweight” rating for the company in a report on Tuesday, May 24th. Finally, Jefferies Financial Group cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Friday.

    Centessa Pharmaceuticals stock traded down $0.05 during midday trading on Monday, hitting $3.18. The stock had a trading volume of 5,782,580 shares, compared to its average volume of 249,128. The stock has a market cap of $299.05 million and a P/E ratio of -1.34. The business has a fifty day moving average price of $7.37 and a 200 day moving average price of $9.13. Centessa Pharmaceuticals has a 12 month low of $2.88 and a 12 month high of $26.90. The company has a current ratio of 21.37, a quick ratio of 21.37 and a debt-to-equity ratio of 0.16.
    Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.09. On average, equities analysts anticipate that Centessa Pharmaceuticals will post -2.48 EPS for the current fiscal year.

    In related news, EVP Antoine Yver sold 20,222 shares of the company’s stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $5.42, for a total value of $109,603.24. Following the completion of the transaction, the executive vice president now directly owns 813,675 shares of the company’s stock, valued at approximately $4,410,118.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.09% of the stock is owned by insiders.

    A number of institutional investors have recently added to or reduced their stakes in CNTA. Point72 Asset Management L.P. boosted its position in shares of Centessa Pharmaceuticals by 263.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,097,908 shares of the company’s stock worth $12,362,000 after acquiring an additional 795,708 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth $167,000. General Atlantic L.P. grew its holdings in Centessa Pharmaceuticals by 545.5% in the third quarter. General Atlantic L.P. now owns 9,681,818 shares of the company’s stock worth $161,686,000 after purchasing an additional 8,181,818 shares during the period. Boxer Capital LLC grew its holdings in shares of Centessa Pharmaceuticals by 47.6% during the third quarter. Boxer Capital LLC now owns 1,334,227 shares of the company’s stock valued at $22,282,000 after buying an additional 430,000 shares during the last quarter. Finally, RA Capital Management L.P. grew its holdings in shares of Centessa Pharmaceuticals by 179.4% during the third quarter. RA Capital Management L.P. now owns 3,577,094 shares of the company’s stock valued at $59,737,000 after buying an additional 2,296,794 shares during the last quarter. 95.72% of the stock is currently owned by hedge funds and other institutional investors.

    About Centessa Pharmaceuticals (Get Rating)

    Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.
2 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.106
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.078
ABO-Group 1 23
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.829
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.804
Aedifica 3 925
Aegon 3.258 323.042
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.349
Air France - KLM 1.025 35.265
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.180
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.748
AMG 971 134.230
AMS 3 73
Amsterdam Commodities 305 6.744
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 495
Antonov 22.632 153.605
Aperam 92 15.047
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.943
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.597
ASML 1.766 109.805
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.833
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.447

Macro & Bedrijfsagenda

  1. 24 maart

    1. Samengestelde inkoopmanagersindex maart (Jap)
    2. Samengestelde inkoopmanagersindex maart (Fra)
    3. Samengestelde inkoopmanagersindex maart (Dld)
    4. Samengestelde inkoopmanagersindex maart (eur)
    5. Samengestelde inkoopmanagersindex maart (VK)
    6. Chicago Fed index februari (VS)
    7. Samengestelde inkoopmanagersindex maart (VS)
  2. 25 maart

    1. Ifo ondernemersvertrouwen maart (Dld)
    2. Case Shiller huizenprijzen januari (VS)
    3. Shell beleggersdag
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht